Activities of Joanna KOPCIŃSKA related to 2019/2816(RSP)
Plenary speeches (1)
Strategic approach to pharmaceuticals in the environment (debate)
Institutional motions (1)
MOTION FOR A RESOLUTION on a strategic approach to pharmaceuticals in the environment
Amendments (10)
Amendment 4 #
Citation 1 a (new)
- having regard to Article 191 (2) of the Treaty on the Functioning of the European Union,
Amendment 13 #
Citation 26 a (new)
- having regard to the Council conclusions of 24 June 2019 on the next steps towards making the EU a best practice region in combatting antimicrobial resistance,
Amendment 31 #
Citation 12 a (new)
- having regard to the OECD study of November 2019 Pharmaceutical Residues in Freshwater - Hazards and Policy Responses,
Amendment 40 #
Recital B
B. whereas the wide use of pharmaceuticals in human and veterinary medicines, including antimicrobial agents, has increased their concentrations in many environmental reservoirs such as soils, sediments and waterbodies in the past 20 years; whereas with changes to the size and age of population this trend may increase; whereas the largest source of pharmaceuticals entering the environment is their use and disposal;
Amendment 58 #
Recital G
G. whereas there is sufficient evidence that action should be taken to reduce the risk from pharmaceuticals in the environment; including the protection of water resources in line with the Water Framework Directive
Amendment 112 #
Paragraph 9
9. Points to the need to regulate pharmaceuticals under water legislation; recalls that interinstitutional negotiations are on-going on a review of the Directive on the quality of water intended for human consumption and on a regulation on minimum requirements for water reuse; asks that regulation for other compartments such as soils be implement as well;
Amendment 141 #
Paragraph 13
13. Calls on the Member States and on the Commission to promote awareness- raising campaigns amongnd training among pharmacists, veterinaries, and physicians on the prudent use of pharmaceuticals, particularly of antimicrobials; calls on actors in the pharmaceutical supply chain to contribute to providing to patients with sufficient information on how incorrectly disposed medicines may negatively impact the environment; calls for on-pack labelling in the form of an appropriate pictogramme to inform consumers how to properly dispose of unused medicines;
Amendment 178 #
Paragraph 20
20. Points to the important role of procurement policy in promoting greener pharmaceuticals in design and manufacturing; calls on the Commission to develop clear guidance on this issue;
Amendment 203 #
Paragraph 27
27. Considers that the overall per capita drug consumption should be reduced, without jeopardising patients’ health; is of the opinion that the overall per animal veterinary medicines consumption should also decrease without compromising animal health and welfare;
Amendment 236 #
Paragraph 32
32. Is concerned that monitoring of pharmaceuticals in the environment, notably in soil, is still very limited; stresses the need to strengthen post-marketing control mechanisms into comprehensive monitoring, also with regard to environmental effects, as the current surveillance system (pharmacovigilance) is not adequately and systematically covering the environmental data deficit;